Summit Therapeutics Share Discussion Threads

[waterloo01] 01/2/2017 09:55

Good to know they are bullish despite a $4.00 downgrade. Catabasis as an outperform looks rather too bullish given yesterdays news.

Oppenheimer lowered its price target on Summit Therapeutics plc (NASDAQ: SMMT) to $24.00 (from $28.00) while maintaining a Outperform rating. The firm said the year of Duchenne Muscular Dystrophy continues and they are bullish on the stock.

Analyst Hartaj Singh commented, "SMMT has two compounds in the clinic, (1) ezutromid, currently in phase 2 development for Duchenne muscular dystrophy (DMD), and (2) ridinilazole, a novel antibiotic for Clostridium difficile infections (CDI), which is concluding a successful Phase 2 program and could potentially enter Phase 3 in 2017. With the recent and ongoing investor interest and focus on Sarepta's (Outperform) Exondys 51 launch and the impending Catabasis (Outperform) edasalonexent Phase 2 clinical readout, we believe investors should add SMMT, another DMD-focused company with an interesting and novel antibiotic to boot, to their biotech diligence list. We are bullish."

[euroto] 01/2/2017 09:48

That seems a bit of speculative gloom HM ?

[hugus maximus] 01/2/2017 09:35

News of the Catabasis CAT-1004 DMD drug P2 trial failure impacts on Sarepta, whose Exondys 51 drug was intended to partner this as a combo drug.

Sarepta seem to have been struggling for support and general enthusiasm for their shares has not been great of late.

Sarepta will have to forward a further $20 million on Summit DMD trial full dosing.(talk of April?) If any ongoing data analysis of Sarepta's FDA approved drug comes back dodgy, shareholders enthusiasm will wain further and one assumes Summit's $500 million part payment may struggle to be met.

I'm not sure of the time table for further news of eteplirsen now their drug is in use ... but if Sarepta ever defaults on future Summit payments, one assumes the European rights will revert back?

Perhaps the $500 million payment may become an issue.

[waterloo01] 31/1/2017 15:01

Like it or not, Trump looks like he'll be helping companies like Summit bigly.

If he does what he says he wants, I can see approvals for ETZ coming much faster than billed. Ditto RDZ, which has an excellent safety profile and could be saving lives in the US tomorrow.

Time for a turnaround in bio on Nasdaq?

[waterloo01] 31/1/2017 12:20

synthetic poop. Wish we had a $bn value attached to RDZ to wipe out!

[freemoney1] 31/1/2017 11:32

H-M, After listening to the recent presentation, and the procedures they have in place for the biopsy testing, I would expect that the time from biopsy to imaging machine and documented results would be fairly quick to maintain the quality of the sample and give them the best chance of a good readout. Any delays I would expect would come from collating all the results and deciding how to interpret and report to the world.... hopefully positive findings. Fingers crossed for all involved. GLA

[euroto] 31/1/2017 11:15

I see the analyst quoted in the above ratings report has the grand score of 0 out of 5.

[hugus maximus] 31/1/2017 10:40

Loving your optimism FM!

Given that there are no reports of 'issues', the first boys should have been given SMTC1100 June / July last year, and the fact that full recruitment is almost there, one assumes that there must already be data accumulating of several boys first 24 week results?

Does anyone have a notion of how many boys need to pass the 24 weeks deadline before it's considered feasible to correlate and release progress info? Surely Q2 will see an RNS as seemingly the schedule is looking good for early info RNS before Q3?

[freemoney1] 31/1/2017 10:13

Cannot find a proper reason for the drop. Just some fear possibly relating to Sarepta and Exondys 51 not being approved by all insurers leading to lack of cash flow.

But I did find this to cheer us LTH's up.Revenue multiply by industry



Drugs (Biotechnology) = 5.82
Drugs (Pharmaceutical) = 4.19

I guess we'd call ourselves a DMD pharmaceutical eventually, so 4.19 x annual sales exceeding $3Billion should give us a decent share price. Fingers cross LTH. :-)

Not too shabby a reason to invest or continue holding for those results :-)

A C.Diff deal in the short term would help underpin the value too!

[freedosh] 27/1/2017 20:58

Well worth listening to. Clear presentation aimed at informed lay audience
Sounds like recruitment nearing completion but would be good to know numbers commenced dosing.

[waterloo01] 27/1/2017 16:45

Sounds like they are close to full recruitment. They will have to RNS once they actually dose the last patient, so maybe 4-6 weeks?

[waterloo01] 27/1/2017 15:22

Anyone listen to the PPMD call in? Wasn't expecting anything new but interested in the tone?

Just posted. Not listened yet.

[luminoso] 26/1/2017 22:47

' All sites are well under way ' - Have we had official news of this ?

[chrisatrdg] 26/1/2017 13:11

Hi H.M. I think you might be right here is hoping !!!!

[hugus maximus] 26/1/2017 12:40

Or perhaps we're too close to important news and there's no chance of directors buying more?

[waterloo01] 26/1/2017 10:30

SP inappropriately weak this AM. Nasdaq pulled down by a couple of 100 share late trades. Hopefully a holding RNS might follow the 2m buy on AIM and 500k shares on Nasdaq (assuming they have finished buying). Given the liquidy here, any II wanting to buy a stake will have to approach 1 of 3 - 4 holders who might be willing to sell (in this case Keith). There just aren't enough shares in free float (or held by holders who are interested in selling).

Hopefully recruitment/dosing will be getting close to being complete and SPRT can hand over a further $20m.

Back to snooze mode.

[hugus maximus] 25/1/2017 17:05

Perhaps AIM was actually getting a little carried away with itself at £2.05 p when the SMMT NASDAQ price is averaging closer to around £1.90 today?

We sadly don't have the comparative volume here to have the boot on our foot.

This is all looking good though ... there's some momentum here now.

[football] 25/1/2017 16:10

SP still up in the US but going down here?

[freedosh] 25/1/2017 14:39

So, it was Robert Keith selling in January.
Now holding 6.9%

[chrisatrdg] 25/1/2017 12:31

Parent Project MD @ParentProjectMD

Join PPMD & @Summitplc on Wed, Jan 25 @ 11am ET for a webinar on utrophin modulation approach for #Duchenne:

…


Eastern time is 5 hrs behind the UK above time in the UK is 4pm this afternoon.

Further exposure for Summit.

Edit : Based on current Buys today could this be the final lighting of the touch paper.

[waterloo01] 25/1/2017 09:15

I note some decent volume on Nasdaq (including two buys totalling about 100k ADR's at full price). ANO fund buying in?

[hugus maximus] 25/1/2017 07:28

Me too euroto ... I just took a quick look through some of the Sarepta Yahoo Finance pages and there's definitely mention of SRPT investors buying into Summit. Perhaps that's where SUMM of the rocket fuel is coming from?

After all this time ... I do wonder if there's some sort of buzz based on anticipated "news"? Whatever it is ... we like it!

[euroto] 25/1/2017 07:20

Well I am enthusiastic for it still after 4 years here.